Author Archives: admin


Stem Cell Clinic > Articles by: admin

Induced Pluripotent Stem Cells | The Progeria Research Foundation

By Induced Pluripotent Stem Cells

The Progeria Research Foundation Cell & Tissue BankHuman Induced Pluripotent Stem Cells (iPSC)

1. iPSC Background information for the non-scientist Stem cells are immature cells that have not yet committed to becoming any one cell type. They are pliable because they have the potential to develop into many different types of mature cells in the body, such as cells that make up the heart or blood vessels, and other tissues and organs. In 2007, researchers discovered a strategy for creating stem cells in the laboratory by reprogramming mature adult cells that we commonly grow for research purposes.1, 2 . These artificially created stem cells are called Induced Pluripotent Stem Cells (iPSCs). For the field of Progeria, this is a huge breakthrough. For the first time, scientists can now make Progeria stem cells and ask questions about how stem cells function and develop in Progeria. Previously there was no source of human Progeria stem cells, and there was therefore a void of information about how Progeria stem cells function compared with stem cells from people without Progeria. In addition, scientists can re-program the Progeria stem cells to create, for the first time, mature Progeria blood vessels, heart cells, and other cell types. Until now, there was no source of human Progeria heart or blood vessel cells. We can now ask key questions about the heart disease that leads to early death in Progeria from heart attacks and strokes. We can compare these discoveries with the heart disease and aging in the general population and discover more about what influences aging in all of us. Already there have been several excellent studies published using Progeria stem cells.3-5 Our goal at The Progeria Research Foundation is to facilitate many more discoveries using this invaluable tool. For a primer on stem cells, please see this US government website: http://stemcells.nih.gov/info/basics/defaultpage.asp

2.Purpose of induced pluripotent stem cell (iPSC) generation and distribution by The Progeria Research Foundation The mission of The Progeria Research Foundation is to discover treatments and the cure for Hutchinson-Gilford Progeria Syndrome and its aging-related disorders. In 2009, PRF entered into a collaboration with an expert team of scientists at the University of Toronto, Canada, under the direction of William Stanford, PhD, to generate high quality Progeria iPSCs. Dr. Stanford is the Canada Research Chair in Integrative Stem Cell Biology. As of 2011, PRF continues to collaborate with Dr. Stanford at the University of Ottawa, Canada where he is Professor of Cellular and Molecular Medicine, Faculty of Medicine, and Senior Scientist at Ottawa Hospital Research Institutes Sprott Centre for Stem Cell Research.

Our goal is to provide this invaluable tool to researchers throughout the world. This new research tool will be used to generate new and innovative research in Progeria, as well as its relationship to heart disease and aging.

3. Generation of Hutchinson-Gilford Progeria Syndrome Induced-Pluripotent Stem Cells (iPSCs) Induced-Pluripotent Stem Cells (iPSCs) were derived using VSVG-pseudotyped retroviral transduction of four human factors, Oct4, Sox2, Klf4, and c-Myc into fibroblasts. iPSC colonies were derived on mouse-embryonic fibroblasts (MEFs). The procedure used was essentially as previously described but without the use of the EOS reporter (Nature Protocols 4: 1828-1844, 2009).

4. Quality Control: Validation and Characterization The lines that are currently available have undergone several validation steps (see downloadable PDFs below):

Additional validation in process: Some lines have completed teratoma assays as shown in supporting data. For all other lines, teratoma assays are in process and status will be updated as these assays are completed.

5. Original starting material from which these iPS cells were derived iPSCs were derived from PRF Cell & Tissue Bank non-transformed fibroblast cell lines.

The transduction method used for all iPS lines was Retrovirus MKOS.

iPSC Line ID

Mutation

Gender and Donation Age

HGADFN003 iPS 1B

LMNAExon 11, 1824 C>T

Male 2yr 0mo

Dermal Fibroblasts HGADFN003

HGADFN003 iPS 1C

LMNA Exon 11, 1824 C>T

Male 2yr 0mo

Dermal Fibroblasts HGADFN003

HGDFN003 iPS 1D

LMNA Exon 11, 1824 C>T

Male 2yr 0mo

Dermal Fibroblasts HGADFN003

HGADFN167 iPS 1J

LMNA Exon 11, 1824 C>T

Male 8yr 5mo

Dermal Fibroblasts HGADFN167

HGADFN167 iPS 1Q

LMNA Exon 11, 1824 C>T

Male 8yr 5mo

Dermal Fibroblasts HGADFN167

HGMDFN090 iPS 1B

Mother of HGADFN167 (unaffected)

Female 37yr 10mo

Dermal Fibroblasts HGMDFN090

HGMDFN090 iPS 1C

Mother of HGADFN167 (unaffected)

Female 37yr 10mo

Dermal Fibroblasts HGMDFN090

HGFDFN168 iPS1 D2

Father of HGADFN167 (unaffected)

Male 40yr 5mo

Dermal Fibroblasts HGFDFN168

HGFDFN168 iPS1P

Father of HGADFN167 (unaffected)

Male 40yr

5mo

Dermal Fibroblasts HGFDFN168

PRF AVAILABLE CELL LINES

6. Join our email list for future iPSC updates and new cell lines We are continuing to generate iPSC lines. If you would like periodic updates on iPSCs held in the PRF Cell & Tissue Bank,please join our emailing list by clicking here

7. Questions? Please contact Leslie Gordon, MD, PhD, Medical Director, with any questions or needs, at lgordon@progeriaresearch.org or 978-535-2594

8. Ordering iPS cell lines

In 2014, PRF instituted a policy of no changes to our MTA. This is the result of 12 years of contractual arrangements with 70 research teams working at institutions in 14 countries. PRF and its counsel have taken into consideration the issues that have arisen in that time period and edited the agreement accordingly, resulting in what we feel are fair and reasonable terms.

For U.S. Federal Government Institutions, please contact Joan Brazier, Research Study Coordinator, at joan_brazier@brown.edu or 401-863-9628.

Step 1: Complete an application and material transfer agreement Application and Agreement for Non-government Institutions

Material Transfer Agreement for Non-government Institutions*

Step 2: Return the completed application and material transfer agreement to PRF at info@progeriaresearch.org. Once approved, you will receive an email confirming your order and anticipated shipping date.

Step 3: Dr. Stanfords laboratory is currently distributing lines as live cultures. His laboratory will email you when the culture has been shipped, with shipping and tracking information. Inexperienced researchers are directed to obtain training at specialized courses essential to human embryonic stem cell/iPSCs work.

Step 4: The University of Ottawa will charge $84.00 per iPSC line plus courier costs, if any, and will send you a bill directly.

9. HGPS and Control iPS Cell Culture Media Preparation Culturing Progeria iPSCs requires the preparation of various kinds of media depending on the growth conditions of the cells and the experimental requirements. In addition to maintenance media, there is also supportive media for the MEFs. The HGPS iPSCs were derived using a Knock-Out medium containing Knock Out Serum Replacement (KOSR).

MEF medium

Store at 4C and use within 4 weeks. If purchasing untreated MEFs from Millipore it is recommended to increase the FBS concentration to 20% for better growth during expansion.

HGPS and Control hiPSC media

Reagent

We recommend Lot testing the Knockout Serum Replacement on established hES cells before being used for Progeria iPS cells.

10. Preparation of HGPS and Control iPSC Culture Surfaces To maintain high quality cells and colonies, it is imperative to passage onto appropriate surfaces. This surface could consist of inactivated mouse embryonic fibroblasts (MEFs, replication arrested through irradiation or mitomycin-c treatment). The protocol for inactivation of MEFs by irradiation follows. However MEFs can also be inactivated by treatment with mitomycin C if there is no access to an irradiator. Inactivated MEFs can be made in house or purchased through Millipore (cat# PMEF-CFL for MEFs that have not been mitotically inactivated or cat# PMEF-CFL for inactivated ones that are ready to use). A vial of untreated MEFs can be expanded and treated with Mitomycin C used immediately or frozen down for future use.

11. Inactivating (by irradiation) and plating MEFs

Materials:

Procedure:

12. Thawing HGPS and Control iPS cell lines One vial of hiPSCs should be thawed into one well of a 6-well plate containing inactivated mouse embryonic feeders cells (MEFs).

Have all tubes, warmed medium, and plates ready before starting the protocol to ensure that the thawing procedure is done as quickly as possible.

Materials:

Procedure:

Note: If only a few undifferentiated colonies are observed after thawing, it may be necessary to select only these colonies for passaging and replate them in the same size well on a new plate.

13. Routine Passaging and Maintenance of Undifferentiated HGPS and Control iPSCs

In order to assure healthy cells, it is important to change their media on a daily basis. This is a simple process of aspirating the old media and replacing it with fresh iPS media. After some time, usually 4-6 days after splitting, it will be necessary to split the cells once again. Splitting cells before they become too confluent will ensure a higher number of undifferentiated cells. Usually a 1:6 or 1:8 split will work well and allow 6-7 days between passages.

14. Suggested Protocol for Passaging iPS CellsUpdated September 4, 2014

The following protocol, obtained from Beers et al, 2012 has been giving excellent results for the team at the Human Pluripotent Stem Cell Facility of Ottawa Hospital Research Institute. According to this team, the protocol has dramatically helped to decrease the differentiated cells that might start to grow and it speeds up the passaging. Cells are often ready within 3 to 5 days instead of 5 to 7. Therefore this could save time and money on media.

EDTA solution: Add 500ul of 0.5M EDTA (pH 8.0) into 500ml of DPBS (-/-). Add 0.9g of NaCl and adjust the osmolarity to 340 mOsm. Filter the solution to sterilize and store it at 4C for up to 6 months. The goal is to create the least amount of disturbance for the cells during dissociation. Therefore the EDTA solution is at the same osmolarity as the E8 media.

Protocol

Add 2ml of E8 media to a 6 well matrigel coated plate.

Take the plate to be passaged and remove the media from the well and wash twice with 1ml of PBS(-/-).

Add 1ml of the EDTA solution to the well and leave for 4min at room temperature.

Once 4 min. is up remove EDTA solution and add 1ml of E8 media.

Scrape cells and divide cells amongst the 6 wells of your plate containing E8 media (Ive been taking 160ul into each well). Avoid breaking up the pieces as much as possible. Preferably use a wide mouth pipette tip.

Swirl and incubate at 37C.

NOTE: Once the cells have been scraped, transfer them to the new plate as soon as possible because the cells will re-attach quickly.

Source:

Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions

Jeanette Beers, Daniel R. Gulbranson, Nicole George, Lauren I. Siniscalchi, Jeffrey Jones, James A. Thomson, and Guokai Chen

Nat Protoc. 2012 Nov; 7(11):2029-40

15. Culturing HGPS and Control iPSCs on MEFs

Materials:

Procedure:

16. Cryopreservation of HGPS and Control iPSCs

Multiple passaging and expansion of iPSCs will result in a surplus of cells. Instead of disposing, it is good practice to freeze cells on occasion to build up a stock and give you cells you can go back to and thaw out for use in the future.

The protocols described below are based on iPSC cultures in 6-well plates where initial clump seeding is adjusted so that wells are 60 70% confluent at time of cryopreservation. Before cryopreservation, iPSCs should be of high quality (primarily undifferentiated with less than 20% of the cells being differentiated). Cryopreservation should be done approximately 1 day before the cells are ready to passage. iPSCs will have improved survival following thawing if cryopreserved as large clumps.

Link:
Induced Pluripotent Stem Cells | The Progeria Research Foundation

Induced Pluripotent Stem Cells for Cardiovascular Diagnostics

By Induced Pluripotent Stem Cells

Nearly 500,000 people in the US die of sudden cardiac death each year, and long QT syndrome (LQTS) is a major form of sudden cardiac death. LQTS can be triggered by drug exposure or stresses. Drug-induced LQTS is the single most common reason for drugs to be withdrawn from clinical trials, causing major setbacks to drug discovery efforts and exposing people to dangerous drugs. In most cases, the mechanism of drug-induced LQTS is unknown. However, there are genetic forms of LQTS that should allow us to make iPS cellderived heart cells that have the key features of LQTS. Our objective is to produce a cell-based test for LQTS with induced pluripotent stem (iPS) cell technology, which allows adult cells to be reprogrammed to be stem celllike cells. Despite the critical need, current tests for drug-induced LQTS are far from perfect. As a result, potentially unsafe drugs enter clinical trials, endangering people and wasting millions of dollars in research funds. When drugs that cause LQTS, such as terfenadine (Seldane), enter the market, millions of people are put at serious risk. Unfortunately, it is very difficult to know when a drug will cause LQTS, since most people who develop LQTS have no known genetic risk factors. The standard tests for LQTS use animal models or hamster cells that express human heart genes at high levels. Unfortunately, cardiac physiology in animal models (rabbits and dogs) differs from that in humans, and hamster cells lack many key features of human heart cells. Human embryonic stem cells (hESCs) can be differentiated into heart cells, but we do not know the culture conditions that would make the assay most similar to LQTS in a living person. These problems could be solved if we had a method to grow human heart cells from people with genetic LQTS mutations, so that we know the exact test conditions that would reflect the human disease. This test would be much more accurate than currently available tests and would help enable the development of safer human pharmaceuticals. Our long-term goal is to develop a panel of iPS cell lines that better represent the genetic diversity of the human population. Susceptibility to LQTS varies, and most people who have life-threatening LQTS have no known genetic risk factors. We will characterize iPS cells with well-defined mutations that have clinically proven responses to drugs that cause LQTS. These iPS cell lines will be used to refine testing conditions. To validate the iPS cellbased test, the results will be directly compared to the responses in people. These studies will provide the foundation for an expanded panel of iPS cell lines from people with other genetic mutations and from people who have no genetically defined risk factor but still have potentially fatal drug-induced LQTS. This growing panel of iPS cell lines should allow for testing drugs for LQTS more effectively and accurately than any current test. To meet these goals, we made a series of iPS cells that harbor different LQTS mutations. These iPS cells differentiate into beating cardiomyocytes. We are now evaluating these LQTS cell lines in cellular assays. We are hopeful that our studies will meet or exceed all the aims of our original proposal.

Read the original here:
Induced Pluripotent Stem Cells for Cardiovascular Diagnostics

At ClinicalTrials.Gov, Untested Stem Cell Clinics …

By Stem Cell Clinics

Stem cell cultures growing in multi well sample tray.

Andrew Brookes/Getty Images

Macular degeneration is the most common cause of vision loss among the elderly. But for some people with the disease, a shot of stem cells to the peeper was all they needed to see again . For others, treatment left them permanently blind . What gives? Stem cell treatments like the one described abovehappening every day in 600 clinics across the USare not approved by the FDA, and in fact have never been tested in a clinical trial.

Eyes arent the only organ getting stabbed full of stem cells. Around the country, more doctors are marketing the therapy to treat everything from diabetes to asthma to erectile dysfunction. The procedure usually involves sucking out some of a patient's fat tissue with a liposuction needle, isolating their stem cells, and reinjecting them back into the place in their body that needs most healing. But because these are living tissues unique to every individual, results may vary. Advocates of the therapy say thats just the cost of doing cutting-edge medicine. Except, any proof they have that it is effective comes from data collected on patients who pay thousands of dollars for the treatment. Usually people pay money for medicine after theres proof it works. In the last few years, some of these stem cell clinicians have begun posting large-scale studies on a government-run website called ClinicalTrials.gov, even though they're often not up to medical research standards or even in compliance with federal regulations. This allows them to masquerade their pay-to-participate studies as legit science.

According to a paper published today by the University of Minnesota, US companies have successfully registered 18 patient-sponsored stem cell studies on that publicly funded website. Only 7 of them disclose that patients pay their own way. None of them list the costs, which can range from $5,000 to $15,000 a treatment, outright. And none of them are actual clinical trials in the randomized, blinded, gold-standard sense of the phrase. Instead, theyre observational studies, based mostly on quality of life questionnaires that ask if youve had any adverse reactions to the procedure.

Leigh Turner, the bioethicist who penned todays perspective and who has become somewhat of a watchdog in the ballooning stem cell clinic industry, says this amounts to hijacking a public good and repurposing it into a free marketing tool. They dont have to pay for ads on television, people just come to them because its this trusted national resource, he says. Its all meant to suggest a seal of approval from the federal government. And thats whats so dangerously misleading, because it doesnt mean that all. It just means someone filled out a form and pressed a button.

Following the passing of the Food and Drug Administration Modernization Act of 1997, the National Library of Medicine established ClinicalTrials.gov to serve as a source of information about publicly and privately supported clinical trials for patients, their families and caregivers, doctors and nurses, and the public. But the NIH doesnt independently verify the scientific validity of any trials posted to the site beyond a limited quality control review. That doesnt really include things like sound study design, compliance with current regulations, or ethical guidelines. In fact, the process is largely automated, and relies almost entirely on the honor system.

Megan Molteni

With 21st Century Cures Act, the Future of Regenerative Medicine Is "Inject and See"

Megan Molteni

The Feds Are Spending Millions to Help You Survive Nuclear War

Anna Vlasits

Scientists Brew Up the Creepiest Batches of Brain Balls Yet

NIH said in a statement that it is continuing to evaluate ways to improve its outreach to make sure that trial participants understand potential risks and benefits. That included adding a prominent disclaimer on the ClinicalTrials.gov homepage in March 2017, stating: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study.

But that hasnt stopped stem cell therapy slingers from touting their clinical bonafides. Cell Surgical Network, an umbrella organization for more than 50 clinics that market the treatment directly to consumers, first registered on ClinicalTrials.gov in October of 2013. At the time, the organization put out a press release noting that the NIH had registered its approved safety study, and that it was now cleared to enroll 3,000 people to study the adverse effects of stem cell treatments on arthritis, cardiomyopathy, Parkinsons, ALS, and a host of other inflammatory and neurological diseases. The ClinicalTrials.gov listing of this study does not mention that research subjects are charged an average of $6000 to participate.

Elliot Lander, a urologist and co-founder of Cell Surgical Network says those costs are necessary because stem cell therapies dont make money like pharmaceuticals dothey can't be packaged up and mass-produced. Which means pharma companies and research institutions arent interested in footing the bill for clinical trials. And he says that while it might be worth noting the costs upfront, the NIH doesnt have a mandatory policy about including fees. Stem cell treatments have no business model, he says. So its left to physicians like myself to do the right thing by my patients, and get them regenerative medicine now, not 10-15 years from now. People dont need to be protected by Leigh Turner, they can do their own due diligence.

So far, at least 6,000 people have followed their due diligence to a treatment at one of Cell Surgical Networks clinics. The network keeps a database of all its patients and their outcomes, hoping for the day when the FDA decides to go from merely ignoring the proliferation of un-approved treatments to giving them a green light based on post-market data (a regulatory middle path floated by advocates like Lander.) In the meantime though, Cell Surgical Network is working with the FDA on an application for a real clinical trial, limited to just knee pain treatmentsthat will even include a randomized placebo. Its going to take us years and a few million dollars, says Lander. The walls are really high for this kind of thing. As they should be.

The rest is here:
At ClinicalTrials.Gov, Untested Stem Cell Clinics ...

Your Stem Cell Questions Answered – webmd.com

By Adult Stem Cells

There's a lot of fiction surrounding stem-cell facts. To separate one from the other, WebMD has consulted experts including Mahendra Rao, MD, PhD, director of the Center for Regenerative Medicine at the National Institutes of Health; Todd McDevitt, PhD, director of the Stem Cell Engineering Center at Georgia Tech; Mary Laughlin, MD, past president of the International Society for Cellular Therapy; and Joshua Hare, MD, director of the Interdisciplinary Stem Cell Institute at the University of Miami.

Here are the questions they answered:

A: The term "stem cells" includes many different kinds of cells.

What they have in common is that they have the ability to make other types of cells. No other cell in the body can do that.

Some stem cells can renew themselves and become virtually any cell in the body. Those are called pluripotent stem cells. They include embryonic stem cells.

Other stem cells don't have as much potential for self-renewal and can't make as many types of cells.

The most basic kind of stem cells are the cells that make up an embryo soon after an egg is fertilized. These stem cells divide over and over, eventually making almost all the different cells in the body.

Adult stem cells, in contrast, are "fully differentiated." That means they are what they are and do what they do. They can't choose another career.

In many organs, however, adult stem cells linger throughout life. They are part of the body's internal repair system. Researchers are still working to discover what adult stem cells from various parts of the body can and can't do. Normally, these relatively rare cells act only on the organ or tissue type in which they are found.

Recently, researchers have learned to reprogram adult cells to become pluripotent cells. These cells, called induced pluripotent cells or iPSCs, have many of the same properties as embryonic stem cells. It's not yet clear whether these cells might carry subtle DNA damage that limits their usefulness.

A: Early in development, a fertilized egg becomes an embryo. The embryo is made up of stem cells that divide over and over again, until these stem cells develop into the cells and tissues that become a fetus.

During in-vitro fertilization, eggs taken from a woman's body are fertilized with sperm cells. If not implanted in a woman's womb, these embryos are discarded.

Researchers have learned to take embryonic stem cells from unused in-vitro fertilizations and, in laboratory culture, to get them to make more embryonic stem cells. Embryonic stem cells are not taken from fertilized eggs or embryos that have been in a woman's womb.

While embryonic stem cells can become any kind of cell in the body, it's unlikely they would be used directly as treatments. Because they have the ability to divide over and over again, they can become rapidly growing tumors. And because they are in such an early stage of development, they take a long time to become functional adult cells.

However, researchers are learning to coax embryonic stem cells to become more mature stem cells. One clinical trial, for example, matures embryonic stem cells into nerve stem cells. These nerve stem cells are being explored as a treatment for Lou Gehrig's disease.

A: Adult stem cells have some advantages. When they come from your own body, your immune system will probably not try to reject them. And adult stem cells aren't controversial.

But there are several main disadvantages to using adult stem cells:

A: A relatively small number of stem cells taken from the body can be grown in the laboratory until they have created millions and millions of new stem cells. This makes it possible for researchers to explore cell-based therapies.

Cell-based therapies, collectively known as regenerative medicine, hold the promise of repairing or even replacing damaged or diseased organs.

Depending on which tissues they come from, stem cells have very different properties. Those from umbilical cord blood are quite different from those from fat, for example.

A: Yes. Stem cells from bone marrow have long been used to treat certain types of leukemia.

The bone marrow is a rich source of blood stem cells. These cells replace the white blood cells crucial to the immune system.

When used for leukemia, the goal is to to wipe out all of a person's white blood cells with radiation and/or chemotherapy -- and then to replace them with a bone marrow transplant from a matched donor. Stem cells from the donor marrow replace the diseased blood cells with healthy blood cells.

A stem cell product designed to avoid the need for a matched donor recently received limited approval in Canada. The product, Prochymal, appears to rescue bone marrow transplant patients who are rejecting their transplant.

In the U.S., the FDA has approved a product called Hemacord, which contains blood stem cells derived from cord blood. The product is approved for patients with diseases that affect their ability to make new blood cells, such as certain blood cancers and immune disorders.

A: That remains to be seen. Potential dangers include:

There is also risk in some of the procedures used to get stem cells out of the body (such as from liposuction or spinal tap) or to deliver stem cells to the body (such as implanting them in the heart, brain, spinal cord, or other organs). That's not so much about the stem cells, but because of the procedures themselves.

Researchers are studying all of that. Without carefully controlled clinical trials, there's no way to know what might happen in the long term, or even in the short term. That's why the FDA discourages the use of stem cells except in clinical trials or approved therapies.

If you are thinking about pursuing stem cell therapy, talk to your doctor first. In the U.S. and abroad, many clinics offer unproven stem cell treatments that have never been tested for safety or effectiveness.

SOURCES:

Mahendra Rao, MD, PhD, director, Center for Regenerative Medicine, National Institutes of Health, Bethesda, Md.

Todd McDevitt, PhD, director, Stem Cell Engineering Center, Georgia Institute of Technology, Atlanta.

Mary Laughlin, MD, past president of the International Society for Cellular Therapy.

Joshua Hare, MD, director, Interdisciplinary Stem Cell Institute, University of Miami.

National Institutes of Health web site.

FDA web site.

More here:
Your Stem Cell Questions Answered - webmd.com

Adult Stem Cell Therapy in Cancer, MSCTC – KUMC

By Adult Stem Cells

HUMAN STUDIES

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G. Haematologica. 2013 May;98(5):765-70. doi: 10.3324/haematol.2012.076075. Epub 2013 Jan 8. FREE ARTICLE

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Lancet Oncol. 2013 Sep;14(10):999-1008. doi: 10.1016/S1470-2045(13)70309-7. Epub 2013 Jul 25. FREE ARTICLE

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. Bone Marrow Transplant. 2013 Jul;48(7):947-52. doi: 10.1038/bmt.2012.276. Epub 2013 Jan 21. FREE ARTICLE

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Korfel A, Elter T, Thiel E, Hnel M, Mhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Rth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L. Haematologica. 2013 Mar;98(3):364-70. doi: 10.3324/haematol.2012.077917. Epub 2012 Dec 14. FREE ARTICLE

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuo MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS. Cancer ImmunolImmunother. 2013 Jan;62(1):125-35. doi: 10.1007/s00262-012-1319-0. Epub 2012 Jul 31. FREE ARTICLE

Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer. VanderWalde A, Ye W, Frankel P, Asuncion D, Leong L, Luu T, Morgan R, Twardowski P, Koczywas M, Pezner R, Paz IB, Margolin K, Wong J, Doroshow JH, Forman S, Shibata S, Somlo G. Biol Blood Marrow Transplant. 2012 Aug;18(8):1273-80. doi: 10.1016/j.bbmt.2012.01.021. Epub 2012 Feb 2. FREE ARTICLE

Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Grupp SA, Prak EL, Boyer J, McDonald KR, Shusterman S, Thompson E, Callahan C, Jawad AF, Levine BL, June CH, Sullivan KE. Clin Cancer Res. 2012 Dec 15;18(24):6732-41. doi: 10.1158/1078-0432.CCR-12-1432. Epub 2012 Oct 23. FREE ARTICLE

IFN--secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway. Yang X, Du J, Xu X, Xu C, Song W. J Immunol Res. 2014;2014:318098. doi: 10.1155/2014/318098. Epub 2014 May 26. FREE ARTICLE

Combinatorial control of transgene expression by hypoxia-responsive promoter and microrna regulation for neural stem cell-based cancer therapy. Luo Y, Zhu D. Biomed Res Int. 2014;2014:751397. doi: 10.1155/2014/751397. Epub 2014 Apr 17. FREE ARTICLE

Effect of NK4 transduction in bone marrow-derived mesenchymal stem cells on biological characteristics of pancreatic cancercells. Sun YP, Zhang BL, Duan JW, Wu HH, Wang BQ, Yu ZP, Yang WJ, Shan YF, Zhou MT, Zhang QY. Int J Mol Sci. 2014 Mar 3;15(3):3729-45. doi: 10.3390/ijms15033729. FREE ARTICLE

Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice. Zhang Y, Wang J, Ren M, Li M, Chen D, Chen J, Shi F, Wang X, Dou J. J Ovarian Res. 2014 Jan 20;7(1):8. doi: 10.1186/1757-2215-7-8. FREE ARTICLE

Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M, Tirughana R, Ghoda LY, Barish ME, Brown CE, Najbauer J, Potter PM, Portnow J, Synold TW, Aboody KS. Stem CellsTransl Med. 2013 Dec;2(12):983-92. doi: 10.5966/sctm.2012-0177. Epub 2013 Oct 28. FREE ARTICLE

Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. J Transl Med. 2013 Jan 24;11:20. doi: 10.1186/1479-5876-11-20. FREE ARTICLE

Mesenchymal stem cells derived from adipose tissue vs bone marrow: in vitro comparison of their tropism towards gliomas. Pendleton C, Li Q, Chesler DA, Yuan K, Guerrero-Cazares H, Quinones-Hinojosa A. PLoS One. 2013;8(3):e58198. doi: 10.1371/journal.pone.0058198. Epub 2013 Mar 12. FREE ARTICLE

Suppression of peritoneal tumorigenesis by placenta-derived mesenchymal stem cells expressing endostatin on colorectal cancer. Zhang D, Zheng L, Shi H, Chen X, Wan Y, Zhang H, Li M, Lu L, Luo S, Yin T, Lin H, He S, Luo Y, Yang L. Int J Med Sci. 2014 Jun 13;11(9):870-9. doi: 10.7150/ijms.8758. eCollection 2014. FREE ARTICLE

Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro. Yang C, Lei D, Ouyang W, Ren J, Li H, Hu J, Huang S. Biomed Res Int. 2014;2014:109389. doi: 10.1155/2014/109389. Epub 2014 May 27. FREE ARTICLE

Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene (PTEN): an imaging demonstration. Yang ZS, Tang XJ, Guo XR, Zou DD, Sun XY, Feng JB, Luo J, Dai LJ, Warnock GL. Onco Targets Ther. 2014 Mar 17;7:441-6. doi: 10.2147/OTT.S59227. eCollection 2014. FREE ARTICLE

Umbilical cord tissue-derived mesenchymal stem cells induce apoptosis in PC-3 prostate cancer cells through activation of JNK and downregulation of PI3K/AKT signaling. Han I, Yun M, Kim EO, Kim B, Jung MH, Kim SH. Stem Cell Res Ther. 2014 Apr 16;5(2):54. [Epub ahead of print] FREE ARTICLE

Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy. Mavroudi M, Zarogoulidis P, Porpodis K, Kioumis I, Lampaki S, Yarmus L, Malecki R, Zarogoulidis K, Malecki M. J Cancer Res Ther (Manch). 2014;2(1):22-33. FREE ARTICLE

Clinical significance of epithelial-mesenchymal transition. Steinestel K, Eder S, Schrader AJ, Steinestel J. ClinTransl Med. 2014 Jul 2;3:17. doi: 10.1186/2001-1326-3-17. eCollection 2014. Review FREE ARTICLE

Role of BMSCs in liver regeneration and metastasis after hepatectomy. Hang HL, Xia Q. World J Gastroenterol. 2014 Jan 7;20(1):126-32. doi: 10.3748/wjg.v20.i1.126. Review. FREE ARTICLE

NKT cells as an ideal anti-tumor immunotherapeutic. Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, Taniguchi M. Front Immunol. 2013 Dec 2;4:409. doi: 10.3389/fimmu.2013.00409. Review. FREE ARTICLE

Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Brennen WN, Denmeade SR, Isaacs JT. EndocrRelatCancer. 2013 Aug 23;20(5):R269-90. doi: 10.1530/ERC-13-0151. Print 2013 Oct. Review FREE ARTICLE

Mesenchymal stem cells as vectors for lung cancer therapy. Kolluri KK, Laurent GJ, Janes SM. Respiration. 2013;85(6):443-51. doi: 10.1159/000351284. Epub 2013 May 23. Review. FREE ARTICLE

Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review). Yi BR, Choi KJ, Kim SU, Choi KC. Int J Oncol. 2012 Sep;41(3):798-804. doi: 10.3892/ijo.2012.1523. Epub 2012 Jun 20. Review. FREE ARTICLE

Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. Bao Q, Zhao Y, Niess H, Conrad C, Schwarz B, Jauch KW, Huss R, Nelson PJ, Bruns CJ. Stem Cells Dev. 2012 Sep 1;21(13):2355-63. doi: 10.1089/scd.2012.0060. Epub 2012 Jun 26. Review FREE ARTICLE

The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Ahmed AU, Alexiades NG, Lesniak MS. CurrOpinMolTher. 2010 Oct;12(5):546-52. Review. FREE ARTICLE

Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Bexell D, Scheding S, Bengzon J. MolTher. 2010 Jun;18(6):1067-75. doi: 10.1038/mt.2010.58. Epub 2010 Apr 20. Review. FREE ARTICLE

Stem cells as vectors for antitumour therapy. Loebinger MR, Janes SM. Thorax. 2010 Apr;65(4):362-9. doi: 10.1136/thx.2009.128025. Review. FREE ARTICLE

Crossing the boundaries: stem cells and gene therapy. Ferguson SD, Ahmed AU, Thaci B, Mercer RW, Lesniak MS. Discov Med. 2010 Mar;9(46):192-6. Review. FREE ARTICLE

Directing systemic oncolytic viral delivery to tumors via carrier cells. Nakashima H, Kaur B, Chiocca EA. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):119-26. doi: 10.1016/j.cytogfr.2010.02.004. Epub 2010 Mar 11. Review. FREE ARTICLE

Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Brenner MK, Okur FV. Hematology Am SocHematolEduc Program. 2009:675-81. doi: 10.1182/asheducation-2009.1.675. Review. FREE ARTICLE

Stem cells as delivery vehicles for oncolytic adenoviral virotherapy. Kranzler J, Tyler MA, Sonabend AM, Ulasov IV, Lesniak MS. Curr Gene Ther. 2009 Oct;9(5):389-95. Review. FREE ARTICLE

Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Duan X, Guan H, Cao Y, Kleinerman ES. Cancer. 2009 Jan 1;115(1):13-22. doi: 10.1002/cncr.24013. Review. FREE ARTICLE

Vector-mediated cancer gene therapy: an overview. Seth P. CancerBiolTher. 2005 May;4(5):512-7. Epub 2005 May 5. Review. FREE ARTICLE

Adenovirus as a gene therapy vector for hematopoietic cells. Marini FC 3rd, Yu Q, Wickham T, Kovesdi I, Andreeff M. Cancer Gene Ther. 2000 Jun;7(6):816-25. Review. FREE ARTICLE

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Clay TM, Custer MC, Spiess PJ, Nishimura MI. PatholOncol Res. 1999;5(1):3-15. Review. FREE ARTICLE

Current status of gene transfer into haemopoietic progenitor cells: application to Langerhans cell histiocytosis. Brenner M. Br J Cancer Suppl. 1994 Sep;23:S56-7. Review. FREE ARTICLE

Last modified: May 22, 2015

Go here to see the original:
Adult Stem Cell Therapy in Cancer, MSCTC - KUMC

Stem Cell Therapy San Antonio TX | Alternative …

By Stem Cell Medicine

Injury Assessment

Do you suffer from pain in your back or your joints, such as hip or knee, which prevents you from living life to the fullest? Is walking, cycling, gardening, fishing, or exercising, no longer possible with out pain? If you are missing out on your Golden Years, you need to see a regenerative medicine physician for a consultation. They can determine if the newest innovations in stem cell therapies are right for you.

The treatment is a simple non-surgical injection into the affected joint with no down time or lengthy recovery. You may maintain your normal lifestyle and allow the cells to create a balanced optimal environment in your joints so your body can repair itself. You should feel maximal results within 10 to 12 weeks at which time you can increase your activity levels to match your comfort, but understand that the regenerative process can continue for long periods of time.

Umbilical cord cells contain growth factors, proteins, and stem cells that continue to produce additional growth factors and proteins for a period of time. These components have the potential to positively affect the environment inside the joint and to stimulate your own tissue to aid in the regenerative process while ALSO stimulating your NATIVE STEM CELLS to aid in regeneration.

Continue reading here:
Stem Cell Therapy San Antonio TX | Alternative ...

Cell Therapy :: Sangamo Therapeutics, Inc. (SGMO)

By Uncategorized

Sangamo has significant experience in process development and manufacturing of modified cell therapy products gained through its T-cell and hematopoietic stem cell (HSC) programs in HIV, which were the first genome editing products to enter human clinical trials. In collaboration with Bioverativ we are also developing modified HSC treatments for beta-thalassemia and sickle cell disease. Cells are removed from the body and undergo ZFN-mediated genome editing. In these autologous therapies, the modified cells are grown and tested before being infused back into the patient.

Modified T-cells have demonstrated spectacular success in treating some cancers. With the exception of two cases these have been autologous therapies. A more useful product would be an off-the-shelf or allogeneic product that could be administered to any patient on diagnosis rather than after precious weeks of manufacturing their own cells. Using our ZFN-mediated genome editing technology to knock out genes that identify these cells as foreign to a patient, we are working to make this possibility a reality.

View original post here:
Cell Therapy :: Sangamo Therapeutics, Inc. (SGMO)

Stem Cell Center Of NJ – New Jersey Stem Cell Therapy

By Stem Cell Medical Center

Connect With Us On Social Media for Website Specials Today!

Shoulder pain from injuries can either be acute or chronic. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

Your back pain has finally caught up with you and youre struggling to reverse the damage. However, regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

If knee pain is derailing your active lifestyle or even your daily activities, then youre not alone. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

Pain can strike in a few locations around the hip. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

NERVE INJURIES pain doesnt fade, your health care provider may recommend surgery to reverse the damage. However, regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

To understand neuropathy, it helps to understand how the nervous system works. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

Erectile Dysfunction (ED) is the inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

Stem Cell Center of NJ specializes in the non-surgical care of acute and chronic pain conditions in the orthopedic field whether its shoulder pain, elbow pain or ankle pain as well as the treatment of erectile dysfunction. In our facility, we utilize the latest research and technology to deliver the best treatment available. Our goal is to help patients restore function and mobility, reduce pain, and ultimately return them back to a life uninhibited by debilitating conditions.

We are very excited to offer our patients Stem Cell Therapy treatments. With Stem Cell Therapy, we harness the bodys innate healing potential to aid in the regeneration and restoration of injured or damaged body tissue. This is a minimally-invasive procedure that utilizes biologics harvested straight from the patient. This means that risk of rejection and infection is extremely rare!

With Stem Cell Therapy, patients no longer have to take heavy medication, endure risky surgical procedures or deal with long recovery periods and months of physical therapy. We have helped numerous patients throughout New Jersey get their lives back with Stem Cell Therapy will you be next?

Read more here:
Stem Cell Center Of NJ - New Jersey Stem Cell Therapy

Platelet-Rich Plasma For Arthritis | Halifax Naturopathic …

By Platelet Rich Plasma Injections

Platelet-rich plasma (PRP) is a therapy which uses a component of a persons own blood to treat their osteoarthritis. PRP is a safe treatment which often gives significant benefit to people suffering from osteoarthritis including improvements in stiffness, pain and mobility.

PRP injections contain a high concentration of your own platelets. These platelets contain a large amount of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-), insulin-like growth factor (IGF), epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF)1.

Table 1. Growth factors involved in tissue repair2.

These growth factors trigger tissue repair in our natural healing and recovery process. When a high concentration of these growth factors is introduced into the area of an injured or arthritic joint the healing process is jump-started.

Some research has suggested that PRP improves the integrity of the joint cartilage by increasing the amount of cartilage producing cells (chondrocytes) and by decreasing their rate of cell death (apoptosis)3. This would conceivably lead to a larger number of chondrocytes actively producing healthy cartilage within the joint and a healthier joint as a result.

PRP is prepared by drawing and centrifuging a small sample of your own blood on the day of treatment. A centrifuge is a device which rapidly rotates, spinning a blood sample at a high speed causing it to separate into layers based on weight. After centrifugation the blood sample separates into a top layer of plasma which is transparent yellow in color (mostly water with some dissolved proteins) and a bottom thick, red layer (red blood cells). At the junction of the plasma and red blood cell layers sits a dense concentration of platelets. This platelet-rich layer of the plasma is the portion of the blood which is collected and used for injection.

PRP is given by injection into the affected site or the site of injury. For example, in cases of tennis elbow the PRP injection is made at the site of the affected common extensor tendon on the elbow and in plantar fasciitis the injection is given at the site of the damaged plantar fascia insertion on the heel of the foot. In the case of osteoarthritis the injury includes two entire joint surfaces. An osteoarthritic joint is treated by injecting PRP into an affected joint space. Since a joint is a closed compartment the PRP fluid stays within the joint, coating the affected joint surfaces and exerting its effect on them through its rich concentration of growth factors.

Many studies have been performed on PRP injections for osteoarthritis and the results have been near-unanimously positive, showing a reduction in pain and improvement in mobility among the people receiving the treatment. In total, 47 studies have investigated PRP as a treatment for osteoarthritis and all 47 of these studies have found that this treatment was beneficial4-50.

Some research has found that 3 PRP injections, with 1 month between each injection, is more effective and gives longer lasting results than only one or two injections31.

Platelet-rich plasma vs hyaluronic acid

Most PRP for osteoarthritis research has been on the knee. To date 37 studies have examined PRPs effect on knee osteoarthritis while the temporomandibular joint has 4 studies, the hip has 3 studies, the ankle has 2 studies and the thumb has 1 study.

Figure 1. Number of studies (by joint) examining platelet-rich plasma for osteoarthritis. Most research performed on knee joint. Although the studies have yet to be done I have also seen good results with osteoarthritis of other joints including the shoulder, wrist and other hand joints.

PRP injection treatments are quite safe, having very little in the way of reported adverse effects50. While most treatments for pain involve a synthetic medication-based therapy, PRP simply uses a component of a persons blood. PRP therefore carries very little risk of causing an allergic reaction. The most common adverse effect of PRP is discomfort at the site of treatment for 1-3 days. This is a common reaction as the mechanism of action of PRP involves a short-term inflammatory phase after treatment which can contribute to discomfort temporarily. As with any injection there is a small chance of infection. There is also a small chance of allergic reaction to the local anesthetic (numbing agent) which is used at the site of the injection.

PRP treatment can provide lasting results for people with osteoarthritis including reduced pain and improved mobility. Typically 3 treatments will be required to attain maximum benefit from PRP. PRP injections can be done 2-4 weeks apart without issue.

PRP injections are a long-term solution for osteoarthritis. While this treatment gives long term benefit some people may experience discomfort following treatment for 1-3 days. In order to deal with this possible discomfort it is best to reduce physical activity after a PRP injection to avoid additional discomfort of the region which was treated. Applying ice to the affected area will not inhibit the effectiveness of the PRP treatment and may help if the treated area is achy or sore.

The treated body part should be rested on the day of treatment and if discomfort remains then 2-3 days of avoiding heavy activity may be required to assist in recovering. Anti-inflammatories such as aspirin, ibuprofen and naproxen in general should not be taken for 2-7 days after a PRP treatment as they could theoretically dampen its effectiveness. Generally acetaminophen (Tylenol) is preferable to anti-inflammatories in this short term to manage any discomfort or pain which may be present.

People with active cancer or active infection are not candidates for PRP treatment. People with thrombocytopenia (low platelets) and people on blood thinners can have PRP treatment but some changes to the treatment may be required.

If you are interested in having PRP treatment contact MacLeod Naturopathic at 902-820-2727 to book an initial consultation with Dr. MacLeod. PRP treatment is also available at Dr. MacLeods location in Port Hood which can be reached at the phone number above.

Naturopathic Doctor at MacLeod Naturopathic

Dr. Colin is a naturopathic doctor practicing in Upper Tantallon in the Halifax Area. He was born and raised in rural Cape Breton and returned to Nova Scotia to practice after finishing his naturopathic education in Toronto. His practice focuses on pain management and maintaining health through physical activity and diet. He utilizes platelet-rich plasma, neural prolotherapy and acupuncture to keep his patients pain-free so that they can stay physically active, social and healthy.

Last updated August 31, 2017

Read more here:
Platelet-Rich Plasma For Arthritis | Halifax Naturopathic ...

Macquarie Stem Cells – Stem Cell Therapy Treatment Sydney …

By Stem Cell Treatment

Based in New South Wales, Macquarie Stem Cells has the knowledge, training and experience to provide stem cell treatment in a safe and positive environment. We boast a team of medical professionals who are passionate about stem cell therapy and its ability to improve your quality of life. Having successfully treated over 700 patients using stem cell medical procedures, you can rely on us to keep your safety and well-being in mind.

When subjected to the right stimulation, stem cells have the remarkable ability to develop into many different specialised cell types, including skin cells, muscle cells, and bone cells. Stem cell treatment involves extracting a tissue sample from your body using a mini-liposuction procedure, removing impurities from the sample such as fat, and then re-injecting it into a specific area. This 3 to 5 hour procedure instigates tissue regeneration in areas affected by issues such as inflammation.

At Macquarie Stem Cells, our aim is to provide stem cell therapy in Sydney that alleviates any pain, discomfort and anxiety you may experience on a day-to-day basis. As one of the leading stem cell treatment clinics around, we can help patients who are suffering a variety of severe and chronic conditions gain a new hold on life. Below is a brief overview of the conditions we can assist with.

Osteoarthritis can be a very complex condition, it is not as black and white as repairing cartilage and expecting improvements in your pain levels. When patients suffer from osteoarthritis, the cartilage begins to thin out and this leads to aggravation in your joints. As the aggravation continues, your synovial fluid can become affected, as well as the surrounding structure of the joints such as the muscles, tendons, ligaments & blood vessels.

We have been working with many professionals and we understand the whole approach to treating and managing osteoarthritis better than anyone else. This treatment will involve follow up from your end, you will need to rebuild lost strength, flexibility of your joints. We will guide you through this.

When the stromal cells are introduced, they will be able to resolve the inflammation within the joint and this will reduce your arthritic pain quite quickly. The cells are also able provide repairs to the synovial membrane; which will help properly lubricate your joints.

We have also observed MRI reports which indicate cartilage regrowth in some patients as well. At this point we need to direct our focus to the surrounding muscles and tendons of the joint, if they are weak and inflexible you may suffer from tendonitis. This does not mean the treatment has gone backwards, it simply means you need to spend some time to rebuild the strength & flexibility you have lost over the years.

The cells have shown a powerful effect on the immune system to the point where they are able to place the immune system in a state of tolerogenesis. Once the immune system attack has settled, the cells are able to target inflamed joints and start their repairs in these areas, thus providing improvements to your pain levels as well as function of the joint. We have regularly observed large changes in patients CRP and RF levels. This has been able to confirm positive changes to inflammation and immune balance within your body.

Some patients suffer from pains such as burning, tingling, electric shocks and similar pains.. even though they are not actually occuring. This indicates the nerve cells are firing but they are not firing due to nociceptive pain (pain which occurs for an external reason). These stromal cells are able to repair the inflammation surrounding the nerve cells and in cases where damage has taken, the cells can differentiate into nerve cells to repair the damage. This will allow the nerves to return to normal function and alleviate the neuropathic pain.

Your body naturally looks to repair any form of damage, however in certain cases it may only be able to do so with scar tissue. Once the stromal cells have homed to the damaged areas of your body, they are able to repair the damaged tissue and differentiate into the surrounding cell types. EG: your body is now able to use the stem cells to repair the torn tendon with actual tendon tissue as opposed to scar tissue. This allows the previously torn tissue to return back to full function.

For pre-exisiting repaired tears, these cells are able to soften the scar tissue formation and allow for a better range of motion whilst reducing the risk of a re-occuring tear adjacent to the existing tear.

Migraines are types of headaches but can be significantly more painful and debilitating. They can also cause a range of other symptoms, including nausea and sensitivity to light or sound. Fortunately, stem cell treatment has the potential to repair inflamed blood vessels which can reduce or eliminate migraines. At this stage we are running a clinical trial, you may place your application to participate in this trial.

We are currently located in Liverpool, NSW. By the end of 2017 we aim to add Darwin, NT into our list of practices. In the meantime we are treating all patients from other states such as VIC, QLD, WA, SA & TAS with a simple application and process over 3 days.

Link:
Macquarie Stem Cells - Stem Cell Therapy Treatment Sydney ...

→←